More relapsing multiple sclerosis (MS) patients treated with Zinbryta (daclizumab) said they felt its health benefits than did those given Avonex (interferon beta-1a) — demonstrating that patient-reported outcomes do mirror objective measures of improved health in a clinical trial of the two drugs. Patient-reported changes in both physical and psychological health contribute to a more comprehensive picture of…

Siemens Healthineers and Biogen will collaborate to develop new magnetic resonance imaging (MRI) applications that can quantify key markers of multiple sclerosis (MS). “By bringing together the shared expertise of both Siemens Healthineers and Biogen in imaging and neurology, respectively, we seek to develop new measurement tools that…

Would you open your bank account and write a blank check to just anyone requesting something of value from you? Of course not. So, why would we do that with our healthcare information? I was recently sent an informed consent form from the MS clinic where I am treated,…

The Multiple Sclerosis (MS) Trust is expressing its disappointment at the recent committee decision of the National Institute for Health and Care Excellence (NICE) to not recommend Zinbryta (daclizumab) be made available as a therapy to MS patients using the public health system in England and Wales. NICE’s preliminary recommendation was based on a review of…

The National Institute for Health and Care Excellence (NICE), the health authority for England and Wales, has decided not to recommend Zinbryta (daclizumab) be made available to multiple sclerosis (MS) patients through the country’s health service. The decision came in a first stage of the drug’s review process, and NICE is welcoming…

Biogen and AbbVie presented positive new post-hoc analysis from the pivotal DECIDE clinical trial, which showed that a significantly larger number of relapsing multiple sclerosis (RMS) patients treated with Zinbryta (daclizumab) had no evidence of disease activity (NEDA) compared to those treated with Avonex (interferon beta-1a). The data were given at the recent 32nd Congress of the European…

At the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016 Congress, taking place in London on Sept. 14–17, Biogen will present the Multiple Sclerosis Cost of Illness study, based on research into more than 16,000 MS patients throughout Europe. The study builds on data from a leading 2005 study that…

Biogen and AbbVie announced that the drug Zinbryta (daclizumab) has received marketing authorization by the European Commission, and is an approved treatment across most of Europe for adults with relapsing forms of multiple sclerosis (MS). Zinbryta is a self-administered, once monthly subcutaneous injection. “Clinical data showed Zinbryta significantly reduced relapses, 24-week…

Biogen, announced that TYSABRI, a drug developed to treat people with multiple sclerosis (MS) has received a positive opinion from the European Medicine Agency (EMA) recommending its approval to be used in people with elapsing-remitting multiple sclerosis (RRMS).

Zinbryta (daclizumab) was approved May 27 for the treatment of adults with relapsing multiple sclerosis (MS). The U.S. Food and Drug Administration (FDA) cleared Biogen’s new long-acting injection as a patient self-administered monthly therapy. The director of Neurology Products at the U.S. FDA’s Center for Drug Evaluation…

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently recommended marketing authorization to Zinbryta (daclizumab) for the treatment of patients with relapsing multiple sclerosis (RMS). Zinbryta (daclizumab HYP) is a humanized monoclonal antibody that is injected every four weeks, and being developed by…

New data presented by Biogen and AbbVie at the recent 68th annual meeting of the American Academy of Neurology (AAN) showed that Zinbryta (daclizumab high-yield process) improved cognitive outcome measures in patients with relapsing forms of multiple sclerosis (RMS). Additional results — from post-hoc analyses of clinical trials — also offer a better…

Biogen reported new data describing the effectiveness of Tecfidera (dimethyl fumarate) in newly diagnosed relapsing-remitting multiple sclerosis (RRMS) patients in a recent presentation at the 68th annual meeting of the American Academy of Neurology (AAN). The conference, taking place in Vancouver, Canada, runs through April 21. Tecfidera is an…

A range of new multiple sclerosis (MS) data from Biogen will be revealed at the 68th annual meeting of the American Academy of Neurology (AAN) in Vancouver, Canada, on April 15–21. Presentations will include studies on Tecfidera (dimethyl fumarate), one of the most frequently used oral MS treatments worldwide, as well as several other…

To celebrate the many family, friends, healthcare professionals, and advocacy communities offering vital support to people living with multiple sclerosis (MS) day after day, MSWorld and Biogen have created the #MySupportHero program. The social media campaign runs through March, MS Awareness Month, to allow people with MS to thank all those who encourage and…

Biogen is launching an initiative developed with the assistance of clinical experts — the 1MSg campaign — to educate and encourage multiple sclerosis (MS) patients to make disease management decisions that are well-informed and based on the latest scientific research. The campaign’s motto is “Take control, known your choices,” and one of its main…

Millions of television viewers who watched the popular HBO mob drama series “The Sopranos” saw actress Jamie Lynn Sigler grow from a teen into a young woman as Meadow Soprano, the independent-minded daughter of mafia boss Tony Soprano, played by the late James Gandolfini. This week, Sigler revealed she has been battling multiple…

A panel of neurologists from the U.K. and Ireland recently developed practical consensus guidelines for monitoring multiple sclerosis (MS) patients on natalizumab (Tysabri) therapy for the risk of developing progressive multifocal leukoencephalopathy (PML), a life-threatening viral infection caused by the John Cunningham (JC) virus. The panel was summoned by…

Recently, Biogen released results from its Phase 2 acute optic neuritis (AON) RENEW trial which tested Anti-LINGO-1. Learn more about this results here. So what is Anti-LINGO-1? According to the MS Society, Anti-LINGO-1 (also known as BIIB033) is a treatment in development by the pharmaceutical company Biogen which is currently…

Biogen Inc. recently reported that the Phase 3 ASCEND clinical trial study testing TYSABRI efficacy in patients with secondary progressive multiple sclerosis (SPMS) did not achieve its primary and secondary goals. According to the company, the comprehensive results of the study will be revealed at a future medical conference.

Advancing key medicinal treatments like TECFIDERA (dimethyl fumarate), the most prescribed oral treatment for multiple sclerosis (MS), is a key focus of a company-wide restructuring recently announced by Biogen, Inc. TECFIDERA has been shown to reduce relapse rates, slow disability progression and the number of brain lesions in patients with relapsing forms…

Lead scientists representing Biogen and AbbVie presented new data on clinical results from the Phase 3 study DECIDE on the compound ZINBRYTA TM at the 31st Congress of the European Committee for Treatment and Research in MS (ECTRIMS) in Barcelona, Spain. The full results of the 2 to 3-year long…

A top MS researcher for Biogen Idec answered questions in an exclusive interview with Multiple Sclerosis News Today correspondent Dr. Ana de Barros at a Satellite Symposia entitled “MS developments: transitioning evidence into clinical practice” presented by the company this morning at the 31st Congress of the European Committee for Treatment and…

Biogen, a biotechnology company focused on innovative therapies for autoimmune disorders, neurodegenerative diseases and hematological conditions, recently announced that it will present new data on its multiple sclerosis (MS) portfolio of therapeutic agents at the upcoming 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis…

Biogen recently announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC), a research-driven pharmaceutical company based in Japan, to exclusively license the company’s experimental product MT-1303. The product is a late stage experimental oral compound developed as a therapy for several autoimmune conditions. MT-1303 is a sphingosine 1-phosphate (S1P)…

Cambridge, Massachusetts based Biogen Inc. has reported its second quarter 2015 results, posting a year-over-year seven percent revenue increase to $2.6 Billion in the quarter. “Biogen remains focused on improving the lives of people living with complex diseases,” says Chief Executive Officer George A. Scangos, Ph.D. “Tecfidera, which is now…

Researchers at Spedali Civili of Brescia in Italy recently published findings in the journal PLoS One that Biogen’s Tysabri (natalizumab) can improve cognitive impairment in patients with relapsing remitting multiple sclerosis (RRMS) over the course of at least three years. The study is entitled “Natalizumab Significantly…

Biogen, a global biotechnology company with over 30 years of clinical excellence in Multiple Sclerosis (MS) research, has recently announced the launch of Reimagine MySelf, a blog dedicated to helping women navigate their daily lives while also dealing with the complications that come with a diagnosis of relapsing MS…

The U.S. Food and Drug Administration (FDA) has announced it will consider marketing approval of ZINBRYTA (daclizumab high-yield process), a potential treatment for relapsing forms of multiple sclerosis (MS). Biogen and AbbVie, who are jointly developing the therapy, have filed a Biologics License Application…

Biogen has recently announced novel results to support the effectiveness of TECFIDERA (dimethyl fumarate) in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). The results revealed that TECFIDERA significantly reduced disability progression and relapses in RRMS patients who received their diagnosis for the first time and had a highly active form of the disease. TECFIDERA…